Hormonal
GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and dual/triple incretin agonists (e.g., tirzepatide, retatrutide) significantly reduce hepatic steatosis and liver enzymes in patients with MASLD, primarily through indirect mechanisms of weight loss and improved insulin resistance, though they may not consistently resolve fibrosis.
If you have MASLD, especially with diabetes or obesity, GLP-1 based therapies (like semaglutide or tirzepatide) are highly effective at reducing liver fat and inflammation. However, do not expect them to reverse advanced scarring (fibrosis) on their own. The benefit comes largely from the weight loss and metabolic control they provide, so they work best when combined with lifestyle changes.
The effects of GLP-1 agonists on MASH may be indirect, resulting from reductions in calorie intake, body weight, and insulin resistance, all of which help decrease liver lipid accumulation and hepatic inflammation... semaglutide... contributed to significant MASH resolution; however, it did not improve the fibrosis stage... tirzepatide decreased liver fat by 8.1% over 52 weeks, along with significant reductions in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase... Retatrutide also improved liver health, as indicated by reductions in plasma ALT and hepatic triglycerides
Why this rating
Based on multiple Phase 2/3 clinical trials (NCT numbers cited) showing consistent biochemical and histological improvements in steatosis, though fibrosis data is mixed.
Source
Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease
Ye Hu et al. · Journal of Clinical and Translational Hepatology · 2024
DOI 10.14218/jcth.2024.00123
More from this paper
- FXR agonists (e.g., obeticholic acid) improve MASH histology but are limited by side effects like pruritus and increased LDL cholesterol.Good
- SGLT2 inhibitors reduce hepatic lipid content and liver enzymes in patients with MASLD and Type 2 Diabetes, but histological evidence for treating MASH is still required.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →